SlideShare a Scribd company logo
1 of 40
ONCOLOGY FOCUSED
IMMUNOTHERAPY
COMPANY
Targeting Cancer
Survivorship
FORWARD LOOKING STATEMENT
This presentation contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but are
not limited to, statements about future expectations, plans and prospects for the
development and commercialization of the Company's product candidates,
including patient enrollment in our clinical trials, present or future licensing,
collaborative or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates are subject
to a number of risks, uncertainties and assumptions, including those identified
under “Risk Factors” in the Company’s most recently filed Annual Report on Form
10-K and Quarterly Report on Form 10-Q and in other filings the
Company periodically makes with the SEC. Actual results may differ materially
from those contemplated by these forward-looking statements. The
Company does not undertake to update any of these forward-looking statements
to reflect a change in its views or events or circumstances that occur after the
date of this presentation.
2
LATE-PHASE, ONCOLOGY FOCUSED
IMMUNOTHERAPY COMPANY
 Targeted, 1st in Class therapies
for prevention of cancer
recurrence
 Focused in large markets in
areas of major unmet medical
need
• Phase 3, PRESENT, breast cancer
clinical trial ongoing under SPA
 Pioneering immunotherapy
technology for cancer
• Induce, activate and cause
proliferation of Cytotoxic T-Cells
• Proven Mechanism of Action
through Expansion of Tumor
Specific CTLs
3
0
5
10
15
20
25
0.5 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5
Year
Hazardofrecurrencebyyearlyinterval
Total
Node 0
Node 1-3
Node (4+)
Tumour size (<1cm)
Tumour size (1.1-3cm)
Tumour size (>3cm)
ER+
ER-
Premen
Postmen
Source: Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351:1451 ; Update of Houghton.
J Clin Oncol. 2005; 23(16S):24s. Abstract 582 Saphner et al., J Clin Oncol. 14: 2738-2746, 1996
DEVELOPMENT PIPELINE
Product Therapeutic Area Phase 1 Phase 2 Phase 3 BLA / NDA
Immunotherapy: Breast Cancer
NeuVax™ (nelipepimut-S)
Node-positive
HER2 IHC 1+/2+
NeuVax™ + Herceptin® Node-positive or node negative/triple
negative HER2 IHC 1+/2+
NeuVax™ + Herceptin® High risk, node-positive or negative,
HER2 IHC 3+
NeuVax™ Ductal Carcinoma in Situ (DCIS)
Immunotherapy: Gastric Cancer
NeuVax™ Gastric, HER2 IHC 1+/2+/3+
Immunotherapy: Gynecological Cancer
GALE-301 Ovarian & Endometrial
GALE-301 + GALE-302 Ovarian & Breast
GALE-301 + GALE-302 Ovarian
Hematology
GALE-401 (Anagrelide CR) MPN-related thrombocytosis
PRESENT
*NeuVax is an investigational product. Efficacy has not been established. Herceptin is a registered trademark of Genentech.
Ongoing Planned
VADIS
4
2b
1b
2b
Adds ~10k patients
>$3B
Combo:
High risk, HER2 3+
NEUVAX:
SIGNIFICANT U.S. COMMERCIAL OPPORTUNITY
5
adds ~10k patients
>$2.5B
Combo Node Pos or Neg
HER2 1+, 2+
HLA-A2, A3, A24, A26
PRESENT
50-60k patients
>$2B
Source: Global Data 2015/Medtrack. Pricing estimates based on a 20% premium to the current average annual price of Herceptin® (U.S. Dollars).
REDEFINING
THE STANDARD
OF CARE
6
NOVEL DEVELOPMENT STRATEGY:
SECONDARY PREVENTION IN CANCER SURVIVORS
7
RECEIVES
PRIMARY
TREATMENT
• Surgery
• Chemotherapy
• and/or Radiation
Disease free
“survivor”
Breast: HER2, 1+/2+
25% recurrence rate in 3 yrs
No FDA Approved
targeted therapies
Breast: HER2, 3+ High
Risk
20% recurrence rate
DECLARED
TO PREVENT
RECURRENCE /
METASTATIC DISEASE
Breast: Ductal Carcinoma in
Situ
8-10% progression to invasive
Ovarian Cancer
~50% recurrence rate in 1 yr
No FDA Approved
targeted therapies
• Watch &
Wait, or
• Repetitive
therapies
TOLD
PREVENTING RECURRENCE:
UNMET MEDICAL NEED
NEUVAX PHASE 3 PRESENT TRIAL DEMOGRAPHIC:
Node positive, Stage 2a - 3a, HER2 1+/2+, HLA A2/A3
Local or Metastatic recurrent disease =
8
Poor prognosis and/or Death
Patients have a ~25% Recurrence Rate
Prevention of recurrences saves lives!
Sources: 1 http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage;
2 Sledge GW Jr: Curing Metastatic Breast Cancer. J Oncol Pract 12:6-10, 2016
5 year survival rate of metastatic cancer = 22%1
“Low Tumor volume” equates to improved overall survival 2
Occult tumor cells  micrometastasis  macrometastisis  metastatic disease
UNIQUELY POSITIONED
 14.5 million cancer survivors in US (NCI
Cancer Survivorship)
• Projected to 19 million survivors in 2024
 Increase in survival due to decades of
productive research, improved
screening/prevention, and effective
treatments
 Survival leads to patients living longer
• 64% alive after 5 years of diagnosis
• 41% alive after 10 years of diagnosis
• 15% alive after 20 years or longer
 Galena peptide vaccines – NeuVax and
GALE-301 are uniquely positioned to
maintain survivorship
9Source: DeSantis CE et al. CA Cancer J Clin 2014: 64:252-271
CANCER
IMMUNOTHERAPY
WITH INNOVATIVE
TECHNOLOGY
Overcoming Cancer by
Activating and Expanding
Cytotoxic T-Cells
10
FIRST-IN-CLASS, TARGETED
IMMUNOTHERAPY PIPELINE
11
Harnessing the
power of the
immune system in
the adjuvant setting
 Exploits specificity
of natural immune
surveillance
 Adjuvant patients
have healthy
immune systems
 Systemic
protection
Goal is to prevent
recurrence
 Recurrences are
almost always
fatal
 Minimal toxicity
and improved
safety profile
 Boosters provide
long term
protective effect
Well-validated
targets
 HER2
 Folate binding
protein (FBP)
Current
Programs
 NeuVax™
(nelipepimut-S)
• Breast: HER2
1+, 2+ and 3+;
DCIS
• Gastric trial
planned
 GALE-301 &
GALE-302
• Ovarian
Adjuvant Setting = Minimal Residual Disease
T-Cell
Activating Receptors Inhibitory Receptors
CD28
OX40
GITR
CD122
CD27
CD360
HVEM
CD137
CTLA-4
PD-1
TIM-3
BTLA
VISTA
LAG-3
IMMUNO-ONCOLOGY:
UNLOCKING THE POWER OF THE T-CELL
12
Checkpoint
inhibitors
Indirect Immune
Modulators
Co-stimulators
Immune Inhibitory
Enzymes
CAR T
Technology
TCR
Technology
TUMOR-SPECIFIC CYTOTOXIC T-CELLS ARE CRUCIAL FOR
EFFICACY OF IMMUNOMODULATORY ANTIBODIES
Peptide based vaccination such as NeuVax effectively
induce, activate and expand Cytotoxic T-Cells (CTLs)
13
Immunomodulatory
antibodies should be
administered when tumor-
specific CTLs are present. If
the number of CTLs is
insufficient, they should be
induced.
Source: Aerts, Cancer Res; 73(8) April 15, 2013 2385
It is evident that approaches
to increase T-Cell expansion,
homing, and effector
functions while
simultaneously targeting
immunosuppression are
needed
T-Cell
Activating Receptors Inhibitory Receptors
CD28
OX40
GITR
CD122
CD27
CD360
HVEM
CD137
CTLA-4
PD-1
TIM-3
BTLA
VISTA
LAG-3
LACK OF REACTIVE T-CELLS MAY RENDER SOME
TOOLS INEFFECTIVE IN MANY CANCERS
14
Checkpoint
inhibitors
Indirect Immune
Modulators
Co-stimulators
Immune Inhibitory
Enzymes
T-Cell
CD28
OX40
GITR
CD122
CD27
CD360
HVEM
CD137
CTLA-4
PD-1
TIM-3
BTLA
VISTA
LAG-3
Activating Receptors Inhibitory Receptors
OUR VACCINES STIMULATE T-CELL
PROLIFERATION AND EXPANSION
15
T
cells
Checkpoint
inhibitors
Indirect Immune
Modulators
Co-
stimulators
Immune
Inhibitory
Enzymes
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
GALE-301
NEUVAX™
(nelipepimut-S)
Targeting HER2
NEUVAX: HER2 IMMUNODOMINANT PEPTIDE
 NeuVax contains the
immunodominant peptide derived
from the extracellular region of the
HER2 protein
 Peptide (aa 369-377)
immunotherapy administered as
intradermal injection
 MHC Class I: HLA A2/A3
17
K I F G S L A F L
ELICITS A STRONG CD8+ T-CELL RESPONSE
 NeuVax binds to antigen
presenting cells (APCs)
 NeuVax stimulates APCs to
activate CD8+ cytotoxic T
lymphocytes (CTLs)
 CTLs rapidly replicate to seek out
and destroy HER2 expressing
tumor cells and micro-metastases
 Booster series maintains long
term immunologic response
 Demonstrated inter- and intra-
antigenic epitope spreading
18
Sources: Peoples GE, et al (2005) JCO, 23(300, 7536-7545; Mittendorf EA, et al
(2006) Surgery, 139(3): 407-418. Peoples, et al, ASCO 2012 Poster Presentation
0.4
1.8
0.7
0.5
0.0
0.5
1.0
1.5
2.0
2.5
%NeuVaxspecificCD8+Tcells
NeuVax Specific CD-8 CTLs: Pre-, Post, Mean and
Long-Term (6 months)
Pre Max Mean Long-Term
POSITIVE SAFETY PROFILE
 NeuVax is well-tolerated in multiple clinical
trials
 Phase 1/2 showed predominantly Grade
1/2 Adverse Events caused by GM-CSF
(n=53)
• Injection site reactions in nearly all patients
demonstrating the activated dendritic cells
• Systemic toxicities caused by GM-CSF
 Fatigue (64%)
 Headache (42%)
 Myalgia/Other Pain (30%)
 August 2015
• Independent Data Monitoring Committee
(IDMC) recommended to the Company that it
can reduce the cardiac toxicity monitoring in
its Phase 3 PRESENT clinical trial
19
Sources: Choy, et al, poster presentation 33rd Annual Chemotherapy Foundation
Symposium: Nov 2015; Mittendorf- Annals of Oncology 25: 1735–1742, 2014
NEUVAX: SN-33 PHASE 2 HER2 IHC 1+/2+
20Source: 2012 San Antonio Breast Cancer Poster, Mazanet, et al.
PHASE 3, PRESENT TRIAL
Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer
with Low to Intermediate Her2 Expression with NeuVax Treatment
 Trial being run under FDA-approved SPA
 Enrollment completed in April 2015 (n=758)
• Adjuvant breast cancer patients, Node Positive, HER2 1+/2+, HLA A2/A3+
 Patient friendly regimen via intradermal injection
• Primary Vaccine Series – injection once a month for 6 months
• Booster Series – injection once every 6 months
 Upcoming Key Milestones
• Interim safety/futility analysis: 2Q16
• Final Endpoint: 2018
21
PHASE 3 PRESENT TRIAL PER SPA
1 2 3 4
Interim analysis
by DSMB at
n=70 events
Endpoint DFS at
n=141 events
/36 months
Dosing by Month + 1 booster
dose every
6 months
thereafter
5 6
Adjuvant breast cancer
patients, randomized 1:1
 Double blind
 Node positive
 HLA A2/A3+
 HER2 IHC 1+/2+
 Stratified by stage, type of
surgery, hormone receptor,
and menopausal status
 Enrollment complete:
n=758 Patients
Study Population + GM-CSF
Placebo + GM-CSF
22
Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with
Low to Intermediate Her2 Expression with NeuVax Treatment
NEUVAX: BREAST CANCER FRANCHISE
Phase Treatment
HER2
Status
Indication Trial Status
Protocol
Defined
# of Patients
Collaborations
3
Single agent
PRESENT
Study
1+, 2+
Node Positive
HLA A2+, A3+
Enrolled
13 countries
~140 centers
700
(enrolled 758)
2b
Combination
with
trastuzumab
1+, 2+
Node Positive or High
Risk Node Negative
HLA A2+, A3+,
A24+, A26+
Enrolling
U.S. only
34 centers
300
2
Combination
with
trastuzumab
3+ high
risk
Node Positive
HLA A2, A3+
Enrolling
U.S. only
30 centers
100
2
Single agent
VADIS Study
1+,
2+,3+
Ductal Carcinoma in
Situ (DCIS)
HLA A2+
Planned
4 U.S. sites
48
23
PRIMARY PREVENTION
Expansion potential for
safe vaccine in DCIS
METASTATIC DISEASE
Expansion potential in
combination with
checkpoint inhibitors
/immune modulators
NEUVAX: ACROSS THE BREAST CANCER
TREATMENT SPECTRUM
24
PROOF OF CONCEPT:
Established in population
with no standard of care
treatment options
SECONDARY PREVENTION
IDEAL SETTING:
Adjuvant treatment in
patient population with
no evidence of disease
MOST ADVANCED:
PRESENT is the largest and
only Phase 3 breast cancer
vaccine trial
Targeting Folate Binding
Protein
GALE-301 &
GALE-302
GALE-301 & GALE-302
26Source: U.S. Ovarian Cancer http://seer.cancer.gov/statfacts/html/ovary.html
 Targeted cancer
immunotherapy
 Folate Binding Protein (FBP) is
over-expressed (20-80 fold) in
>90% of ovarian and
endometrial cancers
 FBP has very limited tissue
distribution and expression in
non-malignant tissue making it
an ideal immunotherapy target
 Current treatments are generic
• Carboplatin and paclitaxel
• High recurrence rate
 Most patients relapse with poor
prognosis
GALE-301/302 FILLS AN UNMET MEDICAL NEED FOR A
SIGNIFICANT NUMBER OF OVARIAN CANCER PATIENTS
27
Limited competition in early stage setting represents a large commercial opportunity
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
2021 2022 2023 2024 2025 2026 2027 2028 2029
Estimated HLA-A2+ Qualified Patient Population
ASSUMPTIONS
• Avg 80% of NED
patients post-surgery
• 70% Penetration
• 80-90% PVS/Booster
compliance
• High Recurrence
rates
• No adjuvant
treatment options
outside chemo
Source: DR/Decision Resources, LLC
CURRENT CLINICAL DEVELOPMENT
28
Phase Treatment Cancer Type
Target
Indication
Current
Status
# of Enrolled
Patients
1/2a GALE-301
Ovarian,
Endometrial
HLA A2+
Ovarian Enrolled 51
1b
GALE-301 &
GALE-302
Ovarian, Breast
HLA A2+
Ovarian Enrolled 39
GALE-301: OPTIMAL DOSE GROUP SHOWS
PRELIMINARY EFFICACY
Source: Peoples, et. al, Poster Presentation, European Cancer Congress 2015 29
Phase 1/2a trial ongoing
 Phase 1: Determined optimal dose and
demonstrated safety and potent immune
response
 Phase 2a Preliminary data in 1000 mcg dose
group:
• At 12 months median follow-up:
 Vaccine group: 2 clinical recurrences
(13.3%) n=15
 Control group: 12 recurrences (55%)
n=22
• Two year DFS estimate in 1000 mcg dose
group is 85.7% vaccine vs. 33.6% control
(p<.02)
• GALE-301 plus GM-CSF is well tolerated
and elicits a strong in vivo immune
response with primarily Grade 1 and
Grade 2 toxicities
2 Year DFS Estimate by Dose Cohort
GALE-301 & GALE 302:
DELAYED-TYPE HYPERSENSITIVITY
30
LEGEND
EE = E39 (GALE-301) x 6 inoculations (n=12)
EE’ = E39 (GALE-301) x 3 inoculations followed by E39’ (GALE-302) x 3 inoculations (n=14)
E’E = E39’ (GALE-302) x 3 inoculations followed by E39 (GALE-301) x 3 inoculations (n=13)
R0 = baseline (pre-vaccination)
RC1 = 1 month after completion of the PVS
RC6 = 6 months after completion of the PVS and pre-booster
Source: Mittendorf et. al., Poster Presentation, Society of the Immunotherapy of Cancer 2015
GALE-401
Anagrelide Controlled
Release (CR)
GALE-401
ANAGRELIDE CONTROLLED RELEASE (CR)
Anagrelide
•Active ingredient
•Reduces the elevated platelet count and the risk of thrombosis in patients with
myeloproliferative neoplasms (MPNs)
•MPNs are hematological malignancies in which the bone marrow cells develop and function
abnormally
Immediate
Release
•Approved for the treatment of patients with thrombocythemia, secondary to MPNs
•IR formulation can cause unacceptable side effects believed to be Cmax-related and has largely
limited the use due to early treatment withdrawal
GALE-401
•Controlled Release (CR) formulation may decrease the frequency or severity of side effects
•Phase 2, Proof-of-Concept Trial Ongoing
•Galena to seek confirmation of the 505(b)(2) regulatory pathway
32
GALE-401:
PHASE 2 PILOT STUDY FINAL RESULTS
33Source: ASH 2015 Poster Presentation, Verstovsek et al.
 Well tolerated with primarily Grade 1 and 2 toxicities in n=14/18
 Efficacy compares favorably to historical anagrelide IR
• Platelet response:
 ORR = 83.3% (15/18)
 CR = 61.1% (11/18)
 PR = 22.2% (4/18)
• Median time to response was 1 to 9 weeks (defined as platelet
count ≤ 600 x109/L)
 Anagrelide IR historical time to response ranged from 4 to 12 weeks
CORPORATE
OVERVIEW
34
1st IN CLASS PROGRAMS WITH EXPANSION
OPPORTUNITIES
 Mid-stage clinical trials have proven T-cell generation
• NeuVax™ (nelipepimut-S) Phase 2 trial demonstrated 2% of the patient’s
T-Cells become CD8+, HER2 directed
• GALE-301 Phase 1/2: Two year DFS estimate in optimal dose group is
85.7% vaccine vs. 33.6% control (p<.02)
 Targeting “high value” settings: Prevention of recurrence in breast
and ovarian cancer are areas of clear unmet medical needs
• No approved drugs for these women with limited late stage competition
 Multiple trials ongoing as stand-alone therapies and in-combination
with other agents
 Breast & Ovarian are just a start – HER2 and Folate Binding
Protein expressed in numerous cancer types
HER2
Breast
Gastric
Prostate
Non-Small Cell
Lung
Bladder
Colorectal
Ovarian
Folate Binding
Protein
Ovarian
Endometrial
Breast
35
LEADERSHIP TEAM
36
 Mark W. Schwartz, Ph.D., President & CEO
Apthera, Bayhill Therapeutics, Calyx Therapeutics,
Trega Biosciences, Incyte Genomics, DuPont
Diagnostics
 Bijan Nejadnik, M.D., Executive Vice President,
Chief Medical Officer Jazz Pharmaceuticals,
Johnson & Johnson, Stanford, Johns Hopkins,
UC Davis
 Remy Bernarda, SVP, Investor Relations &
Corporate Communications
IR Sense, Hana Biosciences, Knight Equity
Markets, Bear Stearns, Goldman Sachs
 Gavin Choy, Pharm.D., SVP, Clinical Sciences &
Operations
Otsuka, Astex, SuperGen, Hana Biosciences,
Gilead, Stanford University Medical Center,
Department of Veteran Affairs
 Tom Knapp, Esq., Interim General Counsel
Sucampo, Exemplar Law Partners,
NorthWestern Energy, Paul Hastings, The
Boeing Company
 Joe Lasaga, VP, Business Development &
Alliance Management
Nektar Therapeutics, Rigel
 Pat Murphy, VP, Regulatory Affairs &
Compliance
Nektar Therapeutics, Bayhill Therapeutics,
Berlex Laboratories, Serono, Parexel, Biogen
2016 MILESTONES
37
PROGRAM MILESTONE
PROJECTED
DATE
NeuVax™
(nelipepimut-S)
Initiate DCIS trial Q1
PRESENT: Reach 70 events Q1
PRESENT: Interim analysis Q2
H&N 1+/2+ Interim safety data Q4
H&N 1+/2+ A24/A26 data Q4
GALE-301
GALE-302
Present 301/302 booster data Q2
Initiate Phase 2b clinical trial Q3
Present GALE-301 Phase 2a two year data Q4
GALE-401
(anagrelide CR)
Confirmation of 505(b)2 pathway 2H
Publish final Phase 2 report Q4
FINANCIAL OVERVIEW
Cash Position (as of 9/30/15) $34.8 million
Divestiture Impact (non-recurring
Q4 to 1H)
$11.75 million income from sale
$5-$6 million expenses to close operations
Legal settlement and associated
expenses (non-recurring Q4 to 1H)
$3-$5 million
Net proceeds from January offering
(Q1)
$20.1 million
Debt (as of 9/30/15) $5.7 million
2016 Projected Quarterly Burn $11-$13 million
Shares Outstanding 182 million
Market Cap (5 February 16) ~$120 million
38
WHY WE’RE HERE
39
Source: E75 vaccine's final tests start in S.A. By Don Finley, January 22, 2012;
Photo credit: Kin Man Hui/San Antonio Express-News/ZUMAPress
“I've had several friends
who've had (breast cancer)
and then…it came back
and they had to go through
treatment again. So this
would be wonderful, not to
have to come back.”
– First NeuVax Phase 3 patient
THANK YOU
NASDAQ: GALE

More Related Content

What's hot

Q1 2017 Presentation
Q1 2017 PresentationQ1 2017 Presentation
Q1 2017 Presentationtargovax2017
 
Targovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegieTargovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegietargovax2017
 
1709 redeye podium_v2
1709 redeye podium_v21709 redeye podium_v2
1709 redeye podium_v2targovax2017
 
1711 trvx nalsd 5min_pitch_v3
1711 trvx nalsd 5min_pitch_v31711 trvx nalsd 5min_pitch_v3
1711 trvx nalsd 5min_pitch_v3targovax2017
 
Redeye Fight Cancer Seminar
Redeye Fight Cancer SeminarRedeye Fight Cancer Seminar
Redeye Fight Cancer Seminartargovax2017
 
Oncology Focused Immunotherapy Company
Oncology Focused Immunotherapy CompanyOncology Focused Immunotherapy Company
Oncology Focused Immunotherapy CompanyGalenabio
 
Pareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare ConferencePareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare Conferencetargovax2017
 
Arming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancerArming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancertargovax2017
 
1712 dnb podium deck
1712 dnb podium deck1712 dnb podium deck
1712 dnb podium decktargovax2017
 
170530 podium-deck arctic-final
170530 podium-deck arctic-final170530 podium-deck arctic-final
170530 podium-deck arctic-finaltargovax2017
 
1711 3 q presentation final
1711 3 q presentation final1711 3 q presentation final
1711 3 q presentation finaltargovax2017
 
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16 Galenabio
 
1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
 
Galena Biopharma Company Presentation
Galena Biopharma Company PresentationGalena Biopharma Company Presentation
Galena Biopharma Company PresentationGalenabio
 
1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backups1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backupstargovax2017
 
Galena presentation 22 sept 16
Galena presentation   22 sept 16Galena presentation   22 sept 16
Galena presentation 22 sept 16Galenabio
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16Galenabio
 

What's hot (20)

Q1 2017 Presentation
Q1 2017 PresentationQ1 2017 Presentation
Q1 2017 Presentation
 
Targovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegieTargovax presentation december 2017 carnegie
Targovax presentation december 2017 carnegie
 
1709 redeye podium_v2
1709 redeye podium_v21709 redeye podium_v2
1709 redeye podium_v2
 
1711 trvx nalsd 5min_pitch_v3
1711 trvx nalsd 5min_pitch_v31711 trvx nalsd 5min_pitch_v3
1711 trvx nalsd 5min_pitch_v3
 
Redeye Fight Cancer Seminar
Redeye Fight Cancer SeminarRedeye Fight Cancer Seminar
Redeye Fight Cancer Seminar
 
Oncology Focused Immunotherapy Company
Oncology Focused Immunotherapy CompanyOncology Focused Immunotherapy Company
Oncology Focused Immunotherapy Company
 
Pareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare ConferencePareto Securities’ 8th Annual Healthcare Conference
Pareto Securities’ 8th Annual Healthcare Conference
 
Arming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancerArming the patient's immune system to fight cancer
Arming the patient's immune system to fight cancer
 
1712 dnb podium deck
1712 dnb podium deck1712 dnb podium deck
1712 dnb podium deck
 
170530 podium-deck arctic-final
170530 podium-deck arctic-final170530 podium-deck arctic-final
170530 podium-deck arctic-final
 
1711 3 q presentation final
1711 3 q presentation final1711 3 q presentation final
1711 3 q presentation final
 
Corporate Presentation
Corporate Presentation Corporate Presentation
Corporate Presentation
 
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16
 
1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett
 
Galena Biopharma Company Presentation
Galena Biopharma Company PresentationGalena Biopharma Company Presentation
Galena Biopharma Company Presentation
 
1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backups1708 2 q presentation v7 uten backups
1708 2 q presentation v7 uten backups
 
Tap Immune Presentation
Tap Immune PresentationTap Immune Presentation
Tap Immune Presentation
 
Galena presentation 22 sept 16
Galena presentation   22 sept 16Galena presentation   22 sept 16
Galena presentation 22 sept 16
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16
 

Viewers also liked

08 16 investor presentation
08 16 investor presentation08 16 investor presentation
08 16 investor presentationinvestorplygem
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2Galenabio
 
Galena presentation 11 jan 17
Galena presentation   11 jan 17Galena presentation   11 jan 17
Galena presentation 11 jan 17Galenabio
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2Galenabio
 
Galena presentation 9 feb 17
Galena presentation   9 feb 17Galena presentation   9 feb 17
Galena presentation 9 feb 17Galenabio
 
Pgem q2 2016 earnings slides final
Pgem q2 2016 earnings slides finalPgem q2 2016 earnings slides final
Pgem q2 2016 earnings slides finalinvestorplygem
 
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final2016 shareholder meeting presentation final
2016 shareholder meeting presentation finalGalenabio
 
Pgem q3 2016 earnings slides final
Pgem q3 2016 earnings slides finalPgem q3 2016 earnings slides final
Pgem q3 2016 earnings slides finalinvestorplygem
 
Galena presentation
Galena presentationGalena presentation
Galena presentationGalenabio
 
Pgem q4 2016 earnings slides final
Pgem q4 2016 earnings slides finalPgem q4 2016 earnings slides final
Pgem q4 2016 earnings slides finalinvestorplygem
 

Viewers also liked (10)

08 16 investor presentation
08 16 investor presentation08 16 investor presentation
08 16 investor presentation
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2
 
Galena presentation 11 jan 17
Galena presentation   11 jan 17Galena presentation   11 jan 17
Galena presentation 11 jan 17
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2
 
Galena presentation 9 feb 17
Galena presentation   9 feb 17Galena presentation   9 feb 17
Galena presentation 9 feb 17
 
Pgem q2 2016 earnings slides final
Pgem q2 2016 earnings slides finalPgem q2 2016 earnings slides final
Pgem q2 2016 earnings slides final
 
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final2016 shareholder meeting presentation final
2016 shareholder meeting presentation final
 
Pgem q3 2016 earnings slides final
Pgem q3 2016 earnings slides finalPgem q3 2016 earnings slides final
Pgem q3 2016 earnings slides final
 
Galena presentation
Galena presentationGalena presentation
Galena presentation
 
Pgem q4 2016 earnings slides final
Pgem q4 2016 earnings slides finalPgem q4 2016 earnings slides final
Pgem q4 2016 earnings slides final
 

Similar to Galena presentation 8 feb 16

Immune-based Therapies for Cancer
Immune-based Therapies for CancerImmune-based Therapies for Cancer
Immune-based Therapies for Cancerflasco_org
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5targovax2017
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentationVincenzo Esposito
 
180606 trvx jef podium final_web
180606 trvx jef podium final_web180606 trvx jef podium final_web
180606 trvx jef podium final_webtargovax2017
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentationoncolyticsinc
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careAdonis Guancia
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentationoncolyticsinc
 
1810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v71810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v7targovax2017
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentationoncolyticsinc
 
2023 HR Positive / HER2-Negative early breast cancer consensus
2023 HR Positive / HER2-Negative early breast cancer consensus2023 HR Positive / HER2-Negative early breast cancer consensus
2023 HR Positive / HER2-Negative early breast cancer consensusssuserc11ccf
 
Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015Company Spotlight
 
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...bkling
 
Vital Signs Edition #6
Vital Signs   Edition #6Vital Signs   Edition #6
Vital Signs Edition #6ScottJordan
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentationoncolyticsinc
 
180528 red eye_podium
180528 red eye_podium180528 red eye_podium
180528 red eye_podiumtargovax2017
 
November 2017 Corporate Presentation
November 2017 Corporate PresentationNovember 2017 Corporate Presentation
November 2017 Corporate Presentationoncolyticsinc
 
Global breast cancer vaccine clinical trial insight
Global breast cancer vaccine clinical trial insightGlobal breast cancer vaccine clinical trial insight
Global breast cancer vaccine clinical trial insightKuicK Research
 
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancerAdjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancerNazia Ashraf
 
Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next levelTaking Immunotherapy to the Next level
Taking Immunotherapy to the Next levelCompany Spotlight
 

Similar to Galena presentation 8 feb 16 (20)

Dendreon.Final
Dendreon.FinalDendreon.Final
Dendreon.Final
 
Immune-based Therapies for Cancer
Immune-based Therapies for CancerImmune-based Therapies for Cancer
Immune-based Therapies for Cancer
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentation
 
180606 trvx jef podium final_web
180606 trvx jef podium final_web180606 trvx jef podium final_web
180606 trvx jef podium final_web
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentation
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_care
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentation
 
1810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v71810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v7
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentation
 
2023 HR Positive / HER2-Negative early breast cancer consensus
2023 HR Positive / HER2-Negative early breast cancer consensus2023 HR Positive / HER2-Negative early breast cancer consensus
2023 HR Positive / HER2-Negative early breast cancer consensus
 
Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015
 
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
 
Vital Signs Edition #6
Vital Signs   Edition #6Vital Signs   Edition #6
Vital Signs Edition #6
 
October 2017 Corporate Presentation
October 2017 Corporate PresentationOctober 2017 Corporate Presentation
October 2017 Corporate Presentation
 
180528 red eye_podium
180528 red eye_podium180528 red eye_podium
180528 red eye_podium
 
November 2017 Corporate Presentation
November 2017 Corporate PresentationNovember 2017 Corporate Presentation
November 2017 Corporate Presentation
 
Global breast cancer vaccine clinical trial insight
Global breast cancer vaccine clinical trial insightGlobal breast cancer vaccine clinical trial insight
Global breast cancer vaccine clinical trial insight
 
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancerAdjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancer
 
Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next levelTaking Immunotherapy to the Next level
Taking Immunotherapy to the Next level
 

Recently uploaded

一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样
一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样
一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样dyuozua
 
Corporate Presentation Probe May 2024.pdf
Corporate Presentation Probe May 2024.pdfCorporate Presentation Probe May 2024.pdf
Corporate Presentation Probe May 2024.pdfProbe Gold
 
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样dyuozua
 
The Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results PresentationThe Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results PresentationLeonardo
 
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样dyuozua
 
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样dyuozua
 
BofA Securities GMM and Steel Conference
BofA Securities GMM and Steel ConferenceBofA Securities GMM and Steel Conference
BofA Securities GMM and Steel ConferenceTeckResourcesLtd
 
一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样
一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样
一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样dyuozua
 
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGORjualobat34
 
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样sovco
 
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样dyuozua
 
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Klinik kandungan
 
一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样
一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样
一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样dyuozua
 
abortion pills in Riyadh+966572737505 Cytotec Riyadh
abortion pills in  Riyadh+966572737505    Cytotec Riyadhabortion pills in  Riyadh+966572737505    Cytotec Riyadh
abortion pills in Riyadh+966572737505 Cytotec Riyadhsamsungultra782445
 
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024KDDI
 
Teck Investor Presentation, April 24, 2024
Teck Investor Presentation, April 24, 2024Teck Investor Presentation, April 24, 2024
Teck Investor Presentation, April 24, 2024TeckResourcesLtd
 
Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024TeckResourcesLtd
 

Recently uploaded (20)

一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样
一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样
一比一原版(Galway毕业证书)爱尔兰高威大学毕业证成绩单原件一模一样
 
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
一比一原版(UNITEC毕业证书)UNITEC理工学院毕业证成绩单原件一模一样
 
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdfITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
 
Corporate Presentation Probe May 2024.pdf
Corporate Presentation Probe May 2024.pdfCorporate Presentation Probe May 2024.pdf
Corporate Presentation Probe May 2024.pdf
 
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
一比一原版(UofT毕业证书)多伦多大学毕业证成绩单原件一模一样
 
The Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results PresentationThe Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results Presentation
 
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
一比一原版(UoA毕业证书)奥克兰大学毕业证成绩单原件一模一样
 
Osisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 ResultsOsisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 Results
 
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
一比一原版(Waikato毕业证书)怀卡托大学毕业证成绩单原件一模一样
 
BofA Securities GMM and Steel Conference
BofA Securities GMM and Steel ConferenceBofA Securities GMM and Steel Conference
BofA Securities GMM and Steel Conference
 
一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样
一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样
一比一原版(QU毕业证书)女王大学毕业证成绩单原件一模一样
 
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
 
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
 
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
一比一原版(VUW毕业证书)惠灵顿维多利亚大学毕业证成绩单原件一模一样
 
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
 
一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样
一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样
一比一原版(AUT毕业证书)奥克兰理工大学毕业证成绩单原件一模一样
 
abortion pills in Riyadh+966572737505 Cytotec Riyadh
abortion pills in  Riyadh+966572737505    Cytotec Riyadhabortion pills in  Riyadh+966572737505    Cytotec Riyadh
abortion pills in Riyadh+966572737505 Cytotec Riyadh
 
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024
 
Teck Investor Presentation, April 24, 2024
Teck Investor Presentation, April 24, 2024Teck Investor Presentation, April 24, 2024
Teck Investor Presentation, April 24, 2024
 
Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024
 

Galena presentation 8 feb 16

  • 2. FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plans and prospects for the development and commercialization of the Company's product candidates, including patient enrollment in our clinical trials, present or future licensing, collaborative or financing arrangements, expected outcomes with regulatory agencies, and projected market opportunities for product candidates are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. 2
  • 3. LATE-PHASE, ONCOLOGY FOCUSED IMMUNOTHERAPY COMPANY  Targeted, 1st in Class therapies for prevention of cancer recurrence  Focused in large markets in areas of major unmet medical need • Phase 3, PRESENT, breast cancer clinical trial ongoing under SPA  Pioneering immunotherapy technology for cancer • Induce, activate and cause proliferation of Cytotoxic T-Cells • Proven Mechanism of Action through Expansion of Tumor Specific CTLs 3 0 5 10 15 20 25 0.5 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 Year Hazardofrecurrencebyyearlyinterval Total Node 0 Node 1-3 Node (4+) Tumour size (<1cm) Tumour size (1.1-3cm) Tumour size (>3cm) ER+ ER- Premen Postmen Source: Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351:1451 ; Update of Houghton. J Clin Oncol. 2005; 23(16S):24s. Abstract 582 Saphner et al., J Clin Oncol. 14: 2738-2746, 1996
  • 4. DEVELOPMENT PIPELINE Product Therapeutic Area Phase 1 Phase 2 Phase 3 BLA / NDA Immunotherapy: Breast Cancer NeuVax™ (nelipepimut-S) Node-positive HER2 IHC 1+/2+ NeuVax™ + Herceptin® Node-positive or node negative/triple negative HER2 IHC 1+/2+ NeuVax™ + Herceptin® High risk, node-positive or negative, HER2 IHC 3+ NeuVax™ Ductal Carcinoma in Situ (DCIS) Immunotherapy: Gastric Cancer NeuVax™ Gastric, HER2 IHC 1+/2+/3+ Immunotherapy: Gynecological Cancer GALE-301 Ovarian & Endometrial GALE-301 + GALE-302 Ovarian & Breast GALE-301 + GALE-302 Ovarian Hematology GALE-401 (Anagrelide CR) MPN-related thrombocytosis PRESENT *NeuVax is an investigational product. Efficacy has not been established. Herceptin is a registered trademark of Genentech. Ongoing Planned VADIS 4 2b 1b 2b
  • 5. Adds ~10k patients >$3B Combo: High risk, HER2 3+ NEUVAX: SIGNIFICANT U.S. COMMERCIAL OPPORTUNITY 5 adds ~10k patients >$2.5B Combo Node Pos or Neg HER2 1+, 2+ HLA-A2, A3, A24, A26 PRESENT 50-60k patients >$2B Source: Global Data 2015/Medtrack. Pricing estimates based on a 20% premium to the current average annual price of Herceptin® (U.S. Dollars).
  • 7. NOVEL DEVELOPMENT STRATEGY: SECONDARY PREVENTION IN CANCER SURVIVORS 7 RECEIVES PRIMARY TREATMENT • Surgery • Chemotherapy • and/or Radiation Disease free “survivor” Breast: HER2, 1+/2+ 25% recurrence rate in 3 yrs No FDA Approved targeted therapies Breast: HER2, 3+ High Risk 20% recurrence rate DECLARED TO PREVENT RECURRENCE / METASTATIC DISEASE Breast: Ductal Carcinoma in Situ 8-10% progression to invasive Ovarian Cancer ~50% recurrence rate in 1 yr No FDA Approved targeted therapies • Watch & Wait, or • Repetitive therapies TOLD
  • 8. PREVENTING RECURRENCE: UNMET MEDICAL NEED NEUVAX PHASE 3 PRESENT TRIAL DEMOGRAPHIC: Node positive, Stage 2a - 3a, HER2 1+/2+, HLA A2/A3 Local or Metastatic recurrent disease = 8 Poor prognosis and/or Death Patients have a ~25% Recurrence Rate Prevention of recurrences saves lives! Sources: 1 http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage; 2 Sledge GW Jr: Curing Metastatic Breast Cancer. J Oncol Pract 12:6-10, 2016 5 year survival rate of metastatic cancer = 22%1 “Low Tumor volume” equates to improved overall survival 2 Occult tumor cells  micrometastasis  macrometastisis  metastatic disease
  • 9. UNIQUELY POSITIONED  14.5 million cancer survivors in US (NCI Cancer Survivorship) • Projected to 19 million survivors in 2024  Increase in survival due to decades of productive research, improved screening/prevention, and effective treatments  Survival leads to patients living longer • 64% alive after 5 years of diagnosis • 41% alive after 10 years of diagnosis • 15% alive after 20 years or longer  Galena peptide vaccines – NeuVax and GALE-301 are uniquely positioned to maintain survivorship 9Source: DeSantis CE et al. CA Cancer J Clin 2014: 64:252-271
  • 10. CANCER IMMUNOTHERAPY WITH INNOVATIVE TECHNOLOGY Overcoming Cancer by Activating and Expanding Cytotoxic T-Cells 10
  • 11. FIRST-IN-CLASS, TARGETED IMMUNOTHERAPY PIPELINE 11 Harnessing the power of the immune system in the adjuvant setting  Exploits specificity of natural immune surveillance  Adjuvant patients have healthy immune systems  Systemic protection Goal is to prevent recurrence  Recurrences are almost always fatal  Minimal toxicity and improved safety profile  Boosters provide long term protective effect Well-validated targets  HER2  Folate binding protein (FBP) Current Programs  NeuVax™ (nelipepimut-S) • Breast: HER2 1+, 2+ and 3+; DCIS • Gastric trial planned  GALE-301 & GALE-302 • Ovarian Adjuvant Setting = Minimal Residual Disease
  • 12. T-Cell Activating Receptors Inhibitory Receptors CD28 OX40 GITR CD122 CD27 CD360 HVEM CD137 CTLA-4 PD-1 TIM-3 BTLA VISTA LAG-3 IMMUNO-ONCOLOGY: UNLOCKING THE POWER OF THE T-CELL 12 Checkpoint inhibitors Indirect Immune Modulators Co-stimulators Immune Inhibitory Enzymes CAR T Technology TCR Technology
  • 13. TUMOR-SPECIFIC CYTOTOXIC T-CELLS ARE CRUCIAL FOR EFFICACY OF IMMUNOMODULATORY ANTIBODIES Peptide based vaccination such as NeuVax effectively induce, activate and expand Cytotoxic T-Cells (CTLs) 13 Immunomodulatory antibodies should be administered when tumor- specific CTLs are present. If the number of CTLs is insufficient, they should be induced. Source: Aerts, Cancer Res; 73(8) April 15, 2013 2385 It is evident that approaches to increase T-Cell expansion, homing, and effector functions while simultaneously targeting immunosuppression are needed
  • 14. T-Cell Activating Receptors Inhibitory Receptors CD28 OX40 GITR CD122 CD27 CD360 HVEM CD137 CTLA-4 PD-1 TIM-3 BTLA VISTA LAG-3 LACK OF REACTIVE T-CELLS MAY RENDER SOME TOOLS INEFFECTIVE IN MANY CANCERS 14 Checkpoint inhibitors Indirect Immune Modulators Co-stimulators Immune Inhibitory Enzymes
  • 15. T-Cell CD28 OX40 GITR CD122 CD27 CD360 HVEM CD137 CTLA-4 PD-1 TIM-3 BTLA VISTA LAG-3 Activating Receptors Inhibitory Receptors OUR VACCINES STIMULATE T-CELL PROLIFERATION AND EXPANSION 15 T cells Checkpoint inhibitors Indirect Immune Modulators Co- stimulators Immune Inhibitory Enzymes T cells T cells T cells T cells T cells T cells T cells T cells T cells GALE-301
  • 17. NEUVAX: HER2 IMMUNODOMINANT PEPTIDE  NeuVax contains the immunodominant peptide derived from the extracellular region of the HER2 protein  Peptide (aa 369-377) immunotherapy administered as intradermal injection  MHC Class I: HLA A2/A3 17 K I F G S L A F L
  • 18. ELICITS A STRONG CD8+ T-CELL RESPONSE  NeuVax binds to antigen presenting cells (APCs)  NeuVax stimulates APCs to activate CD8+ cytotoxic T lymphocytes (CTLs)  CTLs rapidly replicate to seek out and destroy HER2 expressing tumor cells and micro-metastases  Booster series maintains long term immunologic response  Demonstrated inter- and intra- antigenic epitope spreading 18 Sources: Peoples GE, et al (2005) JCO, 23(300, 7536-7545; Mittendorf EA, et al (2006) Surgery, 139(3): 407-418. Peoples, et al, ASCO 2012 Poster Presentation 0.4 1.8 0.7 0.5 0.0 0.5 1.0 1.5 2.0 2.5 %NeuVaxspecificCD8+Tcells NeuVax Specific CD-8 CTLs: Pre-, Post, Mean and Long-Term (6 months) Pre Max Mean Long-Term
  • 19. POSITIVE SAFETY PROFILE  NeuVax is well-tolerated in multiple clinical trials  Phase 1/2 showed predominantly Grade 1/2 Adverse Events caused by GM-CSF (n=53) • Injection site reactions in nearly all patients demonstrating the activated dendritic cells • Systemic toxicities caused by GM-CSF  Fatigue (64%)  Headache (42%)  Myalgia/Other Pain (30%)  August 2015 • Independent Data Monitoring Committee (IDMC) recommended to the Company that it can reduce the cardiac toxicity monitoring in its Phase 3 PRESENT clinical trial 19 Sources: Choy, et al, poster presentation 33rd Annual Chemotherapy Foundation Symposium: Nov 2015; Mittendorf- Annals of Oncology 25: 1735–1742, 2014
  • 20. NEUVAX: SN-33 PHASE 2 HER2 IHC 1+/2+ 20Source: 2012 San Antonio Breast Cancer Poster, Mazanet, et al.
  • 21. PHASE 3, PRESENT TRIAL Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with Low to Intermediate Her2 Expression with NeuVax Treatment  Trial being run under FDA-approved SPA  Enrollment completed in April 2015 (n=758) • Adjuvant breast cancer patients, Node Positive, HER2 1+/2+, HLA A2/A3+  Patient friendly regimen via intradermal injection • Primary Vaccine Series – injection once a month for 6 months • Booster Series – injection once every 6 months  Upcoming Key Milestones • Interim safety/futility analysis: 2Q16 • Final Endpoint: 2018 21
  • 22. PHASE 3 PRESENT TRIAL PER SPA 1 2 3 4 Interim analysis by DSMB at n=70 events Endpoint DFS at n=141 events /36 months Dosing by Month + 1 booster dose every 6 months thereafter 5 6 Adjuvant breast cancer patients, randomized 1:1  Double blind  Node positive  HLA A2/A3+  HER2 IHC 1+/2+  Stratified by stage, type of surgery, hormone receptor, and menopausal status  Enrollment complete: n=758 Patients Study Population + GM-CSF Placebo + GM-CSF 22 Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with Low to Intermediate Her2 Expression with NeuVax Treatment
  • 23. NEUVAX: BREAST CANCER FRANCHISE Phase Treatment HER2 Status Indication Trial Status Protocol Defined # of Patients Collaborations 3 Single agent PRESENT Study 1+, 2+ Node Positive HLA A2+, A3+ Enrolled 13 countries ~140 centers 700 (enrolled 758) 2b Combination with trastuzumab 1+, 2+ Node Positive or High Risk Node Negative HLA A2+, A3+, A24+, A26+ Enrolling U.S. only 34 centers 300 2 Combination with trastuzumab 3+ high risk Node Positive HLA A2, A3+ Enrolling U.S. only 30 centers 100 2 Single agent VADIS Study 1+, 2+,3+ Ductal Carcinoma in Situ (DCIS) HLA A2+ Planned 4 U.S. sites 48 23
  • 24. PRIMARY PREVENTION Expansion potential for safe vaccine in DCIS METASTATIC DISEASE Expansion potential in combination with checkpoint inhibitors /immune modulators NEUVAX: ACROSS THE BREAST CANCER TREATMENT SPECTRUM 24 PROOF OF CONCEPT: Established in population with no standard of care treatment options SECONDARY PREVENTION IDEAL SETTING: Adjuvant treatment in patient population with no evidence of disease MOST ADVANCED: PRESENT is the largest and only Phase 3 breast cancer vaccine trial
  • 26. GALE-301 & GALE-302 26Source: U.S. Ovarian Cancer http://seer.cancer.gov/statfacts/html/ovary.html  Targeted cancer immunotherapy  Folate Binding Protein (FBP) is over-expressed (20-80 fold) in >90% of ovarian and endometrial cancers  FBP has very limited tissue distribution and expression in non-malignant tissue making it an ideal immunotherapy target  Current treatments are generic • Carboplatin and paclitaxel • High recurrence rate  Most patients relapse with poor prognosis
  • 27. GALE-301/302 FILLS AN UNMET MEDICAL NEED FOR A SIGNIFICANT NUMBER OF OVARIAN CANCER PATIENTS 27 Limited competition in early stage setting represents a large commercial opportunity 0 2000 4000 6000 8000 10000 12000 14000 16000 18000 2021 2022 2023 2024 2025 2026 2027 2028 2029 Estimated HLA-A2+ Qualified Patient Population ASSUMPTIONS • Avg 80% of NED patients post-surgery • 70% Penetration • 80-90% PVS/Booster compliance • High Recurrence rates • No adjuvant treatment options outside chemo Source: DR/Decision Resources, LLC
  • 28. CURRENT CLINICAL DEVELOPMENT 28 Phase Treatment Cancer Type Target Indication Current Status # of Enrolled Patients 1/2a GALE-301 Ovarian, Endometrial HLA A2+ Ovarian Enrolled 51 1b GALE-301 & GALE-302 Ovarian, Breast HLA A2+ Ovarian Enrolled 39
  • 29. GALE-301: OPTIMAL DOSE GROUP SHOWS PRELIMINARY EFFICACY Source: Peoples, et. al, Poster Presentation, European Cancer Congress 2015 29 Phase 1/2a trial ongoing  Phase 1: Determined optimal dose and demonstrated safety and potent immune response  Phase 2a Preliminary data in 1000 mcg dose group: • At 12 months median follow-up:  Vaccine group: 2 clinical recurrences (13.3%) n=15  Control group: 12 recurrences (55%) n=22 • Two year DFS estimate in 1000 mcg dose group is 85.7% vaccine vs. 33.6% control (p<.02) • GALE-301 plus GM-CSF is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities 2 Year DFS Estimate by Dose Cohort
  • 30. GALE-301 & GALE 302: DELAYED-TYPE HYPERSENSITIVITY 30 LEGEND EE = E39 (GALE-301) x 6 inoculations (n=12) EE’ = E39 (GALE-301) x 3 inoculations followed by E39’ (GALE-302) x 3 inoculations (n=14) E’E = E39’ (GALE-302) x 3 inoculations followed by E39 (GALE-301) x 3 inoculations (n=13) R0 = baseline (pre-vaccination) RC1 = 1 month after completion of the PVS RC6 = 6 months after completion of the PVS and pre-booster Source: Mittendorf et. al., Poster Presentation, Society of the Immunotherapy of Cancer 2015
  • 32. GALE-401 ANAGRELIDE CONTROLLED RELEASE (CR) Anagrelide •Active ingredient •Reduces the elevated platelet count and the risk of thrombosis in patients with myeloproliferative neoplasms (MPNs) •MPNs are hematological malignancies in which the bone marrow cells develop and function abnormally Immediate Release •Approved for the treatment of patients with thrombocythemia, secondary to MPNs •IR formulation can cause unacceptable side effects believed to be Cmax-related and has largely limited the use due to early treatment withdrawal GALE-401 •Controlled Release (CR) formulation may decrease the frequency or severity of side effects •Phase 2, Proof-of-Concept Trial Ongoing •Galena to seek confirmation of the 505(b)(2) regulatory pathway 32
  • 33. GALE-401: PHASE 2 PILOT STUDY FINAL RESULTS 33Source: ASH 2015 Poster Presentation, Verstovsek et al.  Well tolerated with primarily Grade 1 and 2 toxicities in n=14/18  Efficacy compares favorably to historical anagrelide IR • Platelet response:  ORR = 83.3% (15/18)  CR = 61.1% (11/18)  PR = 22.2% (4/18) • Median time to response was 1 to 9 weeks (defined as platelet count ≤ 600 x109/L)  Anagrelide IR historical time to response ranged from 4 to 12 weeks
  • 35. 1st IN CLASS PROGRAMS WITH EXPANSION OPPORTUNITIES  Mid-stage clinical trials have proven T-cell generation • NeuVax™ (nelipepimut-S) Phase 2 trial demonstrated 2% of the patient’s T-Cells become CD8+, HER2 directed • GALE-301 Phase 1/2: Two year DFS estimate in optimal dose group is 85.7% vaccine vs. 33.6% control (p<.02)  Targeting “high value” settings: Prevention of recurrence in breast and ovarian cancer are areas of clear unmet medical needs • No approved drugs for these women with limited late stage competition  Multiple trials ongoing as stand-alone therapies and in-combination with other agents  Breast & Ovarian are just a start – HER2 and Folate Binding Protein expressed in numerous cancer types HER2 Breast Gastric Prostate Non-Small Cell Lung Bladder Colorectal Ovarian Folate Binding Protein Ovarian Endometrial Breast 35
  • 36. LEADERSHIP TEAM 36  Mark W. Schwartz, Ph.D., President & CEO Apthera, Bayhill Therapeutics, Calyx Therapeutics, Trega Biosciences, Incyte Genomics, DuPont Diagnostics  Bijan Nejadnik, M.D., Executive Vice President, Chief Medical Officer Jazz Pharmaceuticals, Johnson & Johnson, Stanford, Johns Hopkins, UC Davis  Remy Bernarda, SVP, Investor Relations & Corporate Communications IR Sense, Hana Biosciences, Knight Equity Markets, Bear Stearns, Goldman Sachs  Gavin Choy, Pharm.D., SVP, Clinical Sciences & Operations Otsuka, Astex, SuperGen, Hana Biosciences, Gilead, Stanford University Medical Center, Department of Veteran Affairs  Tom Knapp, Esq., Interim General Counsel Sucampo, Exemplar Law Partners, NorthWestern Energy, Paul Hastings, The Boeing Company  Joe Lasaga, VP, Business Development & Alliance Management Nektar Therapeutics, Rigel  Pat Murphy, VP, Regulatory Affairs & Compliance Nektar Therapeutics, Bayhill Therapeutics, Berlex Laboratories, Serono, Parexel, Biogen
  • 37. 2016 MILESTONES 37 PROGRAM MILESTONE PROJECTED DATE NeuVax™ (nelipepimut-S) Initiate DCIS trial Q1 PRESENT: Reach 70 events Q1 PRESENT: Interim analysis Q2 H&N 1+/2+ Interim safety data Q4 H&N 1+/2+ A24/A26 data Q4 GALE-301 GALE-302 Present 301/302 booster data Q2 Initiate Phase 2b clinical trial Q3 Present GALE-301 Phase 2a two year data Q4 GALE-401 (anagrelide CR) Confirmation of 505(b)2 pathway 2H Publish final Phase 2 report Q4
  • 38. FINANCIAL OVERVIEW Cash Position (as of 9/30/15) $34.8 million Divestiture Impact (non-recurring Q4 to 1H) $11.75 million income from sale $5-$6 million expenses to close operations Legal settlement and associated expenses (non-recurring Q4 to 1H) $3-$5 million Net proceeds from January offering (Q1) $20.1 million Debt (as of 9/30/15) $5.7 million 2016 Projected Quarterly Burn $11-$13 million Shares Outstanding 182 million Market Cap (5 February 16) ~$120 million 38
  • 39. WHY WE’RE HERE 39 Source: E75 vaccine's final tests start in S.A. By Don Finley, January 22, 2012; Photo credit: Kin Man Hui/San Antonio Express-News/ZUMAPress “I've had several friends who've had (breast cancer) and then…it came back and they had to go through treatment again. So this would be wonderful, not to have to come back.” – First NeuVax Phase 3 patient

Editor's Notes

  1. Immunodominant Extracellular Domain (aa 1-652)
  2. This image shows single T cell next to a single cancer cell and as we all know, metastatic foci of disease consist of millions of cancer cells so I would contend that it may be difficult to stimulate enough immune response to attack a foci of millions of cancer cells. Instead of developing vaccines like traditional chemotherapies large bulky or metastatic disease, Dr. Peoples and his group has hypothesized that vaccines will be more effective in the adjuvant setting when there is minimal disease.
  3. Looking at the boosted population from SN-33, we can we there is a large treatment difference between the groups in DFS at 36 months. For this analysis the DFS was 36 months, the duration of the booster therapy. This is basically the TPP (target patient population) discussed in the question. Of note, no patients receiving booster inoculations had a recurrence through 36 months, which is the Ph 3 PRESENT study endpoint.